UICMEW | Evaluation Questionnaire UICMEW | Evaluation We greatly value your opinion. Please complete this evaluation and submit it to the registration desk at the conclusion of this activity. Your responses will be used in future planning of activities and materials. Please select the conference attended: * Session 1: January 15, 2025 – Hematologic Malignancies – Update from ASH Session 2: January 22, 2025 – Women and GU Cancers Session 3: January 29, 2025 – Emerging Paradigms in the Management of Oncology Patients I am a: * MD DO PharmD/RPh RN NP NP OtherOther Specialty * Upon completion of this activity I am better able to: Discuss advancements and optimal strategies for bispecific T-cell engagers and novel therapies in Non-Hodgkin Lymphoma (NHL). * Strongly Agree Agree Disagree Strongly Disagree Review novel advancements in CAR T-cell therapy for NHL and leukemias. * Strongly Agree Agree Disagree Strongly Disagree Explain how to optimize treatment selection in Multiple Myeloma (MM), including the use of minimal residual disease (MRD) in the therapeutic setting. * Strongly Agree Agree Disagree Strongly Disagree Review the latest treatment approaches in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML). * Strongly Agree Agree Disagree Strongly Disagree Upon completion of this activity I am better able to: Discuss the current and future applications of newly approved targeted therapies across breast cancer sub-types * Strongly Agree Agree Disagree Strongly Disagree Identify the side effects of innovative, practice-changing therapies and incorporate them into community practice * Strongly Agree Agree Disagree Strongly Disagree Review new diagnostics and treatments in the management of Renal, Urothelial, and Prostate cancers * Strongly Agree Agree Disagree Strongly Disagree Upon completion of this activity I am better able to: Explain the limitations of current registrational studies as they apply to minority populations and FDA guidance for proving this racial disparity (health equity) * Strongly Agree Agree Disagree Strongly Disagree Describe the principles of antibody-drug conjugate therapy and current approved indications * Strongly Agree Agree Disagree Strongly Disagree Discuss the principles of biological cell engagers/cell therapies and current approved indications * Strongly Agree Agree Disagree Strongly Disagree Identify currently approved and emerging diagnostics for early cancer detection and minimal residual disease * Strongly Agree Agree Disagree Strongly Disagree Please indicate the extent of your agreement with the following statements: The faculty for this activity were effective. * Strongly Agree Agree Disagree Strongly Disagree The education resources and/or handouts provided to me at the educational activity are useful to my practice. * Strongly Agree Agree Disagree Strongly Disagree Not Applicable Overall, was this fair, balanced and free from commercial bias? * Yes No (Explain):No (Explain): Of the patients you will see in the next week, about how many will benefit from the information you learned today? * More than 50 26 to 50 11 to 25 1 to 10 Not applicable Based on what I learned today, I will improve my practice by incorporating the following (check all that apply): * Improved diagnosis/patient assessment Useful therapies and appropriate uses Cutting-edge science in this therapeutic area Best practices of my colleagues and leaders I do not plan to make any changes to my practice at this time Other (Explain):Other (Explain): Which ONE delivery method do you find the most effective for CME/CE learning? * Live symposia at national/regional conferences Live local meetings Live grand rounds Internet webcasts Internet/print monographs Other (Explain):Other (Explain): Please rate the professional practice value of each of the following in terms of improving your practice: Today's CME event: * Most Valuable Valuable Somewhat Valuable Least Valuable Direct to consumer advertising: * Most Valuable Valuable Somewhat Valuable Least Valuable Sales representative visits: * Most Valuable Valuable Somewhat Valuable Least Valuable Promotional/other non-certified education: * Most Valuable Valuable Somewhat Valuable Least Valuable Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply): * Lack of knowledge regarding evidence-based strategies Lack of convincing evidence to warrant change Lack of time/resources to consider change Insurance, reimbursement or legal issues Patient adherence/resistance to change Other (Explain):Other (Explain): What motivated you to participate in this activity? (check all that apply) * CME Credits Faculty Topic or Therapeutic area Format Type Other Comments: (Please include 1-3 case-based Questions) Submit If you are human, leave this field blank. Δ